Md Abdus Subhan*

Department of Chemistry, ShahJalal University of Science and Technology, Bangladesh

*Corresponding Author: Md Abdus Subhan, Department of Chemistry, ShahJalal University of Science and Technology, Bangladesh.

Received: May 06, 2021; Published: June 03, 2021

Abstract

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancers. This is because of the lack of estrogen, progesterone receptors and HER2 proteins, which limits the targeted therapy for TNBC. The main therapeutic options are chemotherapy and radiation therapy. However, these treatments are associated with drug resistance and ultimately poor prognosis and reduced survival. It is thus vital to overcome drug resistance and develop targeted therapy for TNBC for enhanced prognosis and prolonged survival. This mini review discusses drug resistance and targeted therapy for TNBC.

Keywords: Breast Cancer; Drug Resistance; Estrogen

References

1. Fernandez J R E., et al. “Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research”. Plos One (2020): 1-8.
2. Hubalek M., et al. “Biological Subtypes of Triple-Negative Breast Cancer”. Breast Care 12 (2017): 8-14.
3. Dai X., et al. “Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping”. Journal of Cancer16 (2017): 3131-3141.
4. Lehmann BD., et al. “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies”. Journal of Clinical Investigation 121 (2011): 2750-2767.
5. Masuda H., et al. “Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes”. Clinical Cancer Research 19 (2013): 5533-5540.
6. Burstein MD., et al. “Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer”. Clinical Cancer Research 21 (2015): 1688-1698.
7. Drew Y., et al. “Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer”. British Journal of Cancer 114 (2016): 723-730.
8. Emens LA., et al. “Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer”. Cancer Research 75 (2015): PD1-6.
9. Nanda R., et al. “Pembrolizumab in patients with advanced triple- negative breast cancer: phase Ib KEYNOTE-012 study”. Journal of Clinical Oncology 34 (2016): 2460-2467.
10. Adams S., et al. “Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)”. Journal of Clinical Oncology 34 (2016): abstr 1009.
11. Vonderheide RH., et al. “Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment associated modulation of inducible costimulator expression on patient T cells”. Clinical Cancer Research 16 (2010): 3485-3494.
12. Pan T., et al. “Silencing of TGIF sensitizes MDA-MB- 231 human breast cancer cells to cisplatin-induced apoptosis”. Experimental and Therapeutic Medicine 3 (2018): 2978-2984
13. Jardin I., et al. “TRPC6 Channels Are Required for Proliferation, Migration and Invasion of Breast Cancer Cell Lines by Modulation of Orai1 and Orai3 Surface Exposure”. Cancers 9 (2018): 331.
14. Zhang L., et al. “Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer”. ACS Applied Materials and Interfaces29 (2020): 32360-32371.
15. Wang L., et al. “Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs)”. Plos One 12 (2017): e0184110.
16. Chen H., et al. “Targeting oncogenic Myc as a strategy for cancer treatment”. Signal Transduction and Targeted Therapy 3 (2018): 5.
17. Logue S E., et al. “Inhibition of IRE RNase activity modulates the tumor cell secretome and enhances response to chemotherapy”. Nature Communications 9 (2018): 3267.
18. Inoue S., et al. “Direct tumor targeting using nanobioconjugate with a combination of monoclonal antibodies for breast cancer treatment”. Cancer Research 69 (2019).

Citation

Citation: Md Abdus Subhan. “Drug Resistance in Triple-Negative Breast Cancer: Strategies to Overcome". Acta Scientific Pharmaceutical Sciences 5.7 (2021): 41-44.

Copyright

Copyright: © 2021 Md Abdus Subhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.